(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of 18.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Ptc Therapeutics's revenue in 2026 is $1,008,754,000.On average, 16 Wall Street analysts forecast PTCT's revenue for 2026 to be $102,239,482,450, with the lowest PTCT revenue forecast at $89,219,597,338, and the highest PTCT revenue forecast at $120,100,094,078. On average, 16 Wall Street analysts forecast PTCT's revenue for 2027 to be $117,846,652,424, with the lowest PTCT revenue forecast at $93,976,863,052, and the highest PTCT revenue forecast at $168,674,280,842.
In 2028, PTCT is forecast to generate $141,716,441,796 in revenue, with the lowest revenue forecast at $106,495,983,352 and the highest revenue forecast at $206,231,641,742.